Bariatric Surgery Combined With GLP-1 Receptor Agonists Study
ConditionObesity
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-60
SponsorChina-Japan Friendship Hospital
About this trial
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits. This study investigates the efficacy and safety of bariatric surgery combined with GLP-1 receptor agonist adjuvant therapy for severe obesity.
Eligibility criteria
Qualifiers
Primary metabolic surgery candidates: Patients undergoing initial laparoscopic sleeve gastrectomy (LSG)
obesity:BMI ≥35 kg/m²
Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria
Age range: 18-60 years (inclusive)
Disqualifiers
Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively
Prior bariatric surgery: History of any metabolic/bariatric surgical procedure
Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak)
Non-indicated candidates: Patients not meeting standard bariatric surgery indications
Trial design
Treatments tested in this trial
- BS-GLP group
- BS group
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov